Flamel Technologies to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston



LYON, France—March 16, 2009 --Flamel Technologies (NASD: FLML) chief executive officer, Stephen H. Willard, is scheduled to present at the 29th Annual Cowen and Company Healthcare Conference in Boston at 3:55 PM today. The presentation will be webcast and may be accessed at the Flamel Technologies website.

The Company also announced today that Mr. Willard is scheduled to ring the opening bell at 9:30 AM, EDT, on Friday, March 20th at NASDAQ's MarketSite in Times Square.

About Flamel Technologies

Flamel Technologies is a drug delivery company with two intellectual property platforms: Micropump, for the controlled release of drugs best absorbed in the small intestine; and Medusa, for the controlled release of proteins, peptides, and other molecules injected subcutaneously. Both of these platforms offer potential advantages with respect to efficacy and the reduction of side-effects, in addition to the obvious benefits associated with more convenient dosing regimens.

Contact:

Charles Marlio, Director of Strategic Planning and Investor Relations
Tel:    (011) (33) 4-7278-3434
Fax:   (011) (33) 4-7278-3435
Marlio@flamel.com

This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007